Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SZ-05
- Development stage
- Phase 2
- Lead developer
- Mazra Mental Health Center
- Administration
- Oral
01
Overview
SZ-05 is an **ambiguous identifier rather than a chemically resolved drug name**. In ClinicalTrials.gov study NCT03323697, it denotes an orally administered Chinese herbal treatment evaluated against escitalopram in a randomized, double-blind study for depression and anxiety. However, a 2025 food-science publication also uses SZ-05 to identify a bioactive fraction derived from *Rabdosia* species in antimicrobial and food-preservation research. The available sources do not establish that these are the same composition, so no unified molecular identity, mechanism, manufacturer, or development program can be assigned.
Beyond the preview
Go deeper on SZ-05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SZ-05.